WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Friday, October 25, 2019

Therapeutic Potential of Cannabinoid Compounds in Parkinson’s and LID Analyzed in Review Study

 OCTOBER 25, 2019     BY MARTA FIGUEIREDO 



Cannabinoid compounds — particularly cannabidiol (CBD) — show potential to ease symptoms in people with Parkinson’s disease and levodopa-induced dyskinesia (LID), according to a review study.
Data also suggests that their therapeutic effects likely involve the direct modulation of critical messenger molecules in the brain and indirect reduction of brain inflammation.
However, future clinical studies are required to confirm these potential benefits in people with Parkinson’s disease and LID.
Parkinson’s disease is characterized by the presence of motor symptoms, including involuntary tremors, slowed movement, rigidity or stiffness, and impaired balance. However, it also can lead to a range of non-motor symptoms.
Long-term treatment with levodopa — the gold standard Parkinson’s therapy — leads to levodopa-induced dyskinesia (LID), or involuntary, jerky movements, in more than 50% of Parkinson’s patients.
Levodopa is used to ease motor symptoms by restoring the loss of dopamine — a key neurotransmitter, or messenger molecule in nerve cells — in these patients.
Both conditions (loss of dopamine and LID) are associated with changes in the basal ganglia, a brain region that contains the substantia nigra and the striatum and is involved in motor function.
Numerous studies over the past decade have looked at cannabis and its active components — known as cannabinoids — as potential treatments for motor symptoms in several neurodegenerative conditions.
Cannabinoids and other players of the endocannabinoid system — a complex modulatory network involved in brain development, memory, movement control, hormone production, and immune reactions — are known to have neuroprotective effects.
That is why “manipulation of the endocannabinoid system could be a promising therapy to control [Parkinson’s disease] and LID symptoms,” the researchers wrote.
A team of Brazilian researchers reviewed preclinical and clinical data on the therapeutic potential of cannabinoid compounds in people with Parkinson’s disease and LID.
Several studies have indicated that the endocannabinoid system — including the endocannabinoid anandamide and cannabinoid receptors — is altered in Parkinson’s patients and animal models of the disease, and that targeting it may prevent loss of dopamine-producing neurons, reduce inflammation, and ease Parkinson’s symptoms.
Evidence of an association between a dysregulated endocannabinoid system and LID is not as strong as that with Parkinson’s, but the team noted that there are still data suggesting that modulating this system, and in particular its receptors, may be a potential therapeutic approach.
“Among the cannabinoids investigated so far, CBD appears one of the most promising drugs in preclinical trials,” the researchers wrote.
CBD, the major non-psychoactive component in cannabis, is involved in a variety of important biologic functions. Preclinical studies have suggested that CBD regulates dopamine-dependent nerve communication by increasing dopamine levels, while decreasing the production of potentially harmful reactive oxygen species and pro-inflammatory molecules.
The team noted that “these anti-inflammatory and antioxidant properties may help explain CBD’s neuroprotective action.”
Most studies of CBD in Parkinson’s animal models have showed that CBD reduced the loss of dopamine-producing neurons and eased motor symptoms. However, others reported no significant benefit.
Data from clinical trials suggest that this cannabinoid eases symptoms in Parkinson’s patients, but a consistent beneficial effect on motor symptoms is still lacking. Furthermore, no clinical study has focused so far on the effects of CBD in reducing LID in people with Parkinson’s disease.
Some studies reported that CBD led to a reduction in psychotic symptoms, and improvements in emotional well-being, cognition, communication, and in mobility and body discomfort in Parkinson’s patients. However, these potential improvements in motor function failed to reflect differences in the total motor score, compared with patients receiving a placebo.
While several case reports, uncontrolled trials, and surveys suggest beneficial effects of cannabinoids in Parkinson’s patients, only four randomized placebo-controlled trials have analyzed the effects of different cannabinoids on Parkinson’s motor symptoms such as akinesia, tremor, or LID. Akinesia is the loss of the ability to move muscles voluntarily.
Only one of these trials, which evaluated the cannabinoid nabilone, showed a clear effect on motor symptoms with an ease in LID. Nabilone is a man-made form of cannabis often used to treat severe nausea and vomiting caused by cancer chemotherapy.
The authors also noted that growing evidence suggests that development of LID is associated with increased neuroinflammation, which may be  potentially caused by levodopa and other Parkinson’s treatments. The beneficial effects of anti-inflammatory medicines to ease LID symptoms also reinforce inflammation’s contribution in LID.
Notably, preclinical studies suggest that a combination of CBD with compounds modulating specific non-cannabinoid receptors — associated with neuroprotective and anti-inflammatory effects and activated by endocannabinoids — may be an effective therapeutic approach to ease Parkinson’s motor symptoms and LID.
More clinical trials are required to clarify the therapeutic effects of cannabinoids in people with Parkinson’s disease and LID, and whether the combination with other compounds modulating neuroinflammation boosts their effects.
https://parkinsonsnewstoday.com/2019/10/25/therapeutic-potential-of-cannabinoid-compounds-in-parkinsons-and-lid-analyzed-in-review-study/

No comments:

Post a Comment